Sugi Predict

Sugi Predict / Compounds / SCHEMBL603315

SCHEMBL603315

SCHEMBL603315

CC(C)(C)OC(=O)N[C@@H]1CC[C@@H](CO)OC1

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 2/20 0.46
▸ KDM1A O60341 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ CTSK P43235 2/20 0.43
▸ GAA P10253 2/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ DRD2 P14416 2/20 0.39
▸ EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30642259 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL12528145 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL4778890 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL30772643 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL603316 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL19898629 1.00 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL12527248 0.88 BTK (0.43) BTKKDM1AMAOBCTSKGAA
SCHEMBL9885693 0.88 BTK (0.43) BTKKDM1AMAOBCTSKGAA
SCHEMBL12527395 0.88 BTK (0.46) BTKKDM1AMAOBCTSKGAA
SCHEMBL22623131 0.87 BTK (0.40) BTKKDM1AMAOBCTSKGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745129-A2 COMPOUND HAVING CYCLIC STRUCTURE Daiichi Sankyo Company, Limited (JP) 2026-05-20 — — EP disclosed
CN-122029153-A Aromatic hydrocarbon receptor modulator compound, and preparation method and application thereof 德明药泰生物技术（深圳）有限公司 2026-05-12 — — CN disclosed
EP-3682881-B1 COMPOUND HAVING CYCLIC STRUCTURE DAIICHI SANKYO CO LTD (JP) 2026-04-01 — — EP disclosed
US-20260022123-A1 Methods of Making Modified BTK Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2026-01-22 — — US disclosed
EP-4169575-B1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMA (JP) 2026-01-07 — — EP disclosed
WO-2025217420-A1 PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF ZENO MANAGEMENT, INC. (US) 2025-10-16 — — WO disclosed
EP-4626554-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF Tiger Biotherapeutics Inc. (US) 2025-10-08 — — EP disclosed
WO-2025101598-A1 BI-CYCLIC PYRIMIDINE COMPOUNDS, METHODS AND USES THEREOF ZENO MANAGEMENT, INC. (US) 2025-05-15 — — WO disclosed
US-12297187-B2 Compound having cyclic structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-05-13 — — US disclosed
WO-2025082312-A1 AROMATIC HYDROCARBON RECEPTOR MODULATOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 德明药泰生物技术（深圳）有限公司 2025-04-24 — — WO disclosed
US-20120115841-A1 BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 — — US disclosed
US-20120040989-A1 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY ACTELION PHARMACEUTICALS LTD. (CH) 2012-02-16 — — US disclosed
US-20110245259-A1 5-Amino-2-(1-Hydroxy-Ethyl)-Tetrahydropyran Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-10-06 — — US disclosed
US-20110245259-A1 5-Amino-2-(1-Hydroxy-Ethyl)-Tetrahydropyran Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-10-06 — — US disclosed
US-7981886-B2 Antibiotics derivatives ACTELION PHARMACEUTICAL LTD. (CH) 2011-07-19 — — US disclosed
US-20100179135-A1 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-15 — — US disclosed
WO-2010067332-A1 5-AMINO-2-(1-HYDROXY-ETHYL)-TETRAHYDROPYRAN DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-06-17 — — WO disclosed
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 — — US disclosed
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 — — US disclosed
US-20080280888-A1 Antibiotics Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-11-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115841-A1 BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS FPR1, FPR2, FPR3 BTK 2745/4885KDM1A 4126/4885MAOB 1502/4885
US-20120040989-A1 2-HYDROXYETHYL-1H-QUINOLIN-2-ONE DERIVATIVES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY NQO2, AZI2, Q6ZSR9 BTK 2821/4885KDM1A 84/4885MAOB 1653/4885
US-20260022123-A1 Methods of Making Modified BTK Inhibitors BTK, TEC, SYK BTK 1/4885KDM1A 334/4885MAOB 1823/4885
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity AAAS, AMPD2, AMPD3 BTK 953/4885KDM1A 602/4885MAOB 1474/4885
US-12297187-B2 Compound having cyclic structure H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B BTK 1678/4885KDM1A 1456/4885MAOB 575/4885
US-20080280888-A1 Antibiotics Derivatives NR4A1, NR2C2, NR4A3 BTK 1795/4885KDM1A 1522/4885MAOB 1079/4885
US-20110245259-A1 5-Amino-2-(1-Hydroxy-Ethyl)-Tetrahydropyran Derivatives CD2, CD22, DRD3 BTK 1295/4885KDM1A 1068/4885MAOB 2323/4885
US-20100179135-A1 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRAN DERIVATIVES ELANE, AAAS, DNPEP BTK 3316/4885KDM1A 4344/4885MAOB 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.